Learn what deucravacitinib is, how this first-in-class selective TYK2 inhibitor works, and why it’s changing the treatment landscape for moderate-to-severe plaque psoriasis and other autoimmune diseases, with data from pivotal phase 3 clinical trials.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs